Beam Therapeutics

BEAM

Precision medicineBiotech & pharmaceuticals

$25.70vs prev close▲+1.10(+4.47%)

$20.2352W Range$38.26

30% from low

+0.46 (+1.89%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

4 buys

Concentrated buys

1M net buy

+$4.9M

≈ +197K shares

Portfolio Weight

1.68%

1M -0.13%p

Holding ETFs

2 ETFs

ARKG · ARKK

Price Effect (Buy)

Shares increased, but price decline reduced portfolio weight.

Shares +36.2% · Market value +18.7% · Weight -0.13%p

Trade Intensity

Concentrated buys

Basis: 0 sells · 4 buys in 1M · weight -0.13%p decrease

Trade Log4-day BUY streak

Date	Action	ETF	Shares	Close	Est. total
26.10.09	BUY	ARKG	19,510	$25.70	$501.4K
26.09.23	BUY	ARKG	65,553	$24.37	$1.6M
26.09.22	BUY	ARKG	9,519	$25.93	$246.8K
26.09.21	BUY	ARKG	102,565	$25.26	$2.6M
26.09.09	BUY	ARKG · ARKK	271,159	$25.17	$6.8M
26.09.08	BUY	ARKG · ARKK	263,163	$26.83	$7.1M
26.07.16	BUY	ARKG	29,375	$28.39	$834.0K
26.07.15	BUY	ARKG	32,751	$30.84	$1.0M
26.07.14	BUY	ARKG	14,820	$30.89	$457.8K
26.07.13	BUY	ARKG	82,392	$31.00	$2.6M
26.06.09	BUY	ARKK	21,873	$30.47	$666.5K
26.06.08	BUY	ARKK	15,114	$29.78	$450.1K
26.06.05	BUY	ARKK	87,414	$29.40	$2.6M
26.03.25	SELL	ARKK	99,745	$23.12	$2.3M
26.03.24	SELL	ARKK	27,716	$23.95	$663.8K

10.09BUY

19,510

ARKGClose$25.70Est. total$501.4K

09.23BUY

65,553

ARKGClose$24.37Est. total$1.6M

09.22BUY

9,519

ARKGClose$25.93Est. total$246.8K

09.21BUY

102,565

ARKGClose$25.26Est. total$2.6M

09.09BUY

271,159

ARKG · ARKKClose$25.17Est. total$6.8M

09.08BUY

263,163

ARKG · ARKKClose$26.83Est. total$7.1M

07.16BUY

29,375

ARKGClose$28.39Est. total$834.0K

07.15BUY

32,751

ARKGClose$30.84Est. total$1.0M

07.14BUY

14,820

ARKGClose$30.89Est. total$457.8K

07.13BUY

82,392

ARKGClose$31.00Est. total$2.6M

06.09BUY

21,873

ARKKClose$30.47Est. total$666.5K

06.08BUY

15,114

ARKKClose$29.78Est. total$450.1K

06.05BUY

87,414

ARKKClose$29.40Est. total$2.6M

03.25SELL

99,745

ARKKClose$23.12Est. total$2.3M

03.24SELL

27,716

ARKKClose$23.95Est. total$663.8K

1 / 10

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

11,346,013

Portfolio Weight

1.68%

in ETF 2.94%

Est. Value

$291M

30D Net

+$19M

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Strong Buy

Buy

Hold

Analyst Targets

avg.

$52.15

vs Current ▲ +106.7% upside

Current$25.23

Low ~ High$26.00 ~ $80.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Wedbush

Outperform

$65.00

+157.63%

—

Maintain

2026-09-09

HC Wainwright & Co.

Buy

$80.00

+217.08%

—

Maintain

2026-08-25

B of A Securities

Buy

$47.00

+86.29%

—

Maintain

2026-07-08

HC Wainwright & Co.

Buy

$80.00

+217.08%

—

Maintain

2026-07-07

Bernstein

Outperform

$39.00

+54.58%

—

Maintain

2026-05-13

1 / 4

Avg Target

$52.15

vs Current ▲ +106.7% upside

Strong Buy

15 analysts

Strong Buy 1Buy 12Hold 2

Low $26.00

Current $25.23

High $80.00

Firm	Position	Target	Upside	Close	Action	Date
Wedbush	Outperform	$65.00	+157.63%	—	Maintain	26.09.09
HC Wainwright & Co.	Buy	$80.00	+217.08%	—	Maintain	26.08.25
B of A Securities	Buy	$47.00	+86.29%	—	Maintain	26.07.08
HC Wainwright & Co.	Buy	$80.00	+217.08%	—	Maintain	26.07.07
Bernstein	Outperform	$39.00	+54.58%	—	Maintain	26.05.13

1 / 4

Price Information

Previous Close$24.60

Open$24.72

Day Range$24.55 - $26.23

52-Week Range$20.23 - $38.26

1-Year Change1.22%

Trading Volume

Volume1,798,758

Avg Volume (3mo)1,898,343

Valuation

Market Cap2.7B

Book Value$10.69

Shares Outstanding103,287,665

Financials

Revenue (TTM)156.0M

Net Income-86,520,000

EPS$-0.68

EBITDA-355,780,992

Profitability

P/E Ratio-

P/B Ratio2.41

Return on Equity (ROE)-8.18%

Return on Assets (ROA)-17.01%

Profit Margin-55.45%

EV/EBITDA-4.67

Beta2.20

Dividend

Dividend Rate-

Dividend Yield0.00%

Technical

RSI(14)53.23

Company Overview

Beam Therapeutics is a biotechnology company developing precision genetic medicines for serious diseases. Their main products include novel base editing therapies for sickle cell disease, alpha-1 antitrypsin deficiency, and glycogen storage disease 1a, with a pipeline targeting various genetic disorders. Beam is positioned as an innovator in the field of genetic medicine, with strategic collaborations with major pharmaceutical companies.

P/B

2.41

Price-to-Book

ROE

-8.2%

Net loss

Beta

2.20

Extreme volatility

RSI(14)

53.2

Neutral

AI-generated summary. Not investment advice.

Beam Therapeutics

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks